

A study of management of ovarian tumours at tertiary health care centre

Dr Sanjay Kumar Gupta¹, Dr Neelam Singh², Dr Meenakshi Devi³, Dr Amita Yadav⁴, Dr Pradeep Kumar Singh⁵, Tariq Khan⁶

1. Dr Sanjay Kumar Gupta, Associate Professor, Department of Anaesthesia, Prasad Medical College, Junab Ganj, Lucknow UP, sanjay218@hotmail.com
2. Dr Neelam Singh, Assistant Professor, Department of Obstetrics and Gynaecology, Rani Durgawati Medical College, Banda, UP, Apnatva789@Gmail.Com
3. Dr Meenakshi Devi, Assistant Professor, Department of Obstetrics and Gynaecology, Rani Durgawati Medical College, Banda, UP, verma.meenakshi9936@gmail.com
4. Dr Amita Yadav, Associate Professor, Department of Obstetrics and Gynaecology, Rani Durgawati Medical College, Banda, UP
5. Dr Pradeep Kumar Singh, E.M.O., Rani Durgawati Medical College, Banda, UP
6. Tariq Khan, Rani Durgawati Medical College, Banda, UP

Corresponding Author:

Dr Neelam Singh, Assistant Professor, Department of Obstetrics and Gynaecology, RDMC, Banda, UP, Apnatva789@Gmail.Com

Abstract

Background: Advanced ovarian cancer surgery presents anaesthetists with the challenge of managing patients with potential multiple co-morbidities undergoing major open or extended laparoscopic surgeries. The disease has overall amongst the poorest overall survival rates of all malignancies, with an estimated 5-year survival rate of <43%, and the patients being of a generally older age group present specific challenges in terms of their accumulated co-morbidities. **Aim and objective:** To study the management of patients with ovarian tumours at a tertiary health care centre **Methodology:** This study was carried out over a period of 1 years from 2023 to 2024 and includes 50 patients with ovarian tumour. Data was collected with pretested questionnaire. Data included sociodemographic data, clinical history and clinical examination. Management was done as per type of ovarian tumours. The complications of ovarian tumour were observed. Data analysed with appropriate statistical tests. **Results:** The incidence of ovarian tumour was 5.14. In the study 68% were benign tumours, whereas 32% were malignant. Most common mode of management of ovarian tumour was cystectomy (46%).

Keyword: ovarian tumours, anaesthesia, Management, peri-operative medicine

Introduction

Ovarian cancer generally presents late, due to nonspecific symptoms [1]. Consequently, it has amongst the poorest overall survival rates of all gynaecological and other malignancies, with an estimated 5-year survival rate of 42.6% in the United Kingdom [2]. Ovary is the vital organ concerned with the reproductive capacity of the individual. Ovarian tumours are common form of neoplasms in women accounting for about 30% of genital tract tumours. Ovarian tumour is the 6th most common cancer in humans and most frequent cause of death in gynaecological cancer. About

70% tumours occur in reproductive age group. Ovarian cancer is 2nd most common malignancy of female genital tract after Carcinoma of cervix. It accounts for 10-15% of total genital malignancies in India. [3] It kills more women every year than cancer of all genital sites combine.[4] High mortality rate due to ovarian cancer can be attributed to advanced stage at the time of presentation and failure of complete resection of tumour at the time of surgery. Hence, it is crucial to have a fair idea regarding the nature of tumour, benign or malignant at the therapeutic stage so that the primary surgery can be optimally planned and undertaken. The problem of pre-operative diagnosis of the ovarian tumour has not yet been completely solved.[5]

Specially in resources limited settings in India. This results inevitably in some patients having suboptimal oncoreductive surgeries and other being under staged and at risk of under treatment.[6] Due to often asymptomatic nature of the early stage of the disease, many cases of the ovarian tumours present in advanced stage for which 5 year survival rate remains low. Up to 70% of the cases are detected in advanced stages in which mortality rate reaches 70% in 2 years and 90% in 5 years. This has encouraged research into ovarian tumour research methods. Ovarian tumours commonly present as adnexal mass. An adnexal mass refers to any mass occupying a region of the uterine appendages (adnexa). The accurate diagnosis of ovarian tumours is challenging for gynaecologist because of atypical behaviour. Preoperative diagnostic procedure that are able to distinguish whether an ovarian tumour is benign or malignant could be useful in planning and optimizing treatment. Pre-operative assessment of ovarian mass is generally done by bimanual pelvic examination (for its size, shape, consistency, mobility and tenderness), ultrasonography (transabdominal or transvaginal with or without Doppler), computerised tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET) and tumour markers (CA-125, CA-15-3, CA-19-9). Among these, CT scan, MRI and PET scan are costly investigations, the availability and affordability cannot be ensured specially in resource limited settings like developing countries. These individual parameters have varying sensitivity and specificity. Any patient with ovarian mass with more than 10 cms in size requires surgical exploration. Ovarian cyst of lesser size in the premenopausal age group can be followed up clinically for few months, for expected resolution of functional cysts.

Postmenopausal women with complex ovarian mass more than 6 cms requires surgical exploration since there is increased risk of malignancy. Due to high prevalence and case fatality ratio of ovarian tumour even in good hospital set up, early diagnosis and treatment becomes very necessary. The present study will be undertaken to review common clinical, histological presentation and management of patients of ovarian tumours.

MATERIAL AND METHODS

Present study was a prospective observational study carried out at a tertiary health care centre. Study was carried out during 2023 to 2024. All the patients admitted in the obstetrics and gynaecology department in Rani Durgawati Medical College, Banda, UP.

Inclusion Criteria:

All patients with solid ovarian mass detected clinically and ultrasound examination. All patients with cystic ovarian lesions more than 6 cms.

Exclusion criteria:

Ovarian cyst less than 6 cms with clear cysts in reproductive age group.

Study was approved by ethical committee of the institute. A valid written consent was taken from patients after explaining study to them. Data was collected with pretested questionnaire. Data included sociodemographic data, clinical history. A thorough clinical examination was done. All patients underwent routine investigations for surgery. Histopathological reports and ultrasonographic findings were noted. The tumour marker levels of suspicious tumours were tested. The intra- operative findings were noted. Management was done as per type of ovarian tumours. The gross and histopathological study of the specimen was done. The co-relation between preoperative, intra- operative and post operative findings was done. The complications of ovarian tumour were observed. Data was analysed with appropriate statistical tests.

RESULTS

There were total 973 gynaecology admissions in institute during study period, out of which 50 were ovarian tumours. So the incidence was 5.14%. In present study, most common clinical presentation was pain in abdomen (62%), followed by abdominal mass (84%). Most of the ovarian tumour patients presented with more than one symptoms. Pressure symptoms included retention of urine, increased frequency of micturation, gastrointestinal symptoms like constipation. In present study, maximum cases were having unilateral ovarian tumours (62%). In present study, among the 50 patients with ovarian tumours, 34 cases (68%) were benign tumours, whereas 16 cases (32%) were malignant. In present study on ultrasonographic examination maximum findings were suggestive of cystic + solid consistency (34%), followed by cystic consistency (32%). Least common were liver metastasis (4%). In present study, 38% of the patients had tumour marker CA-125 positive whereas the remaining 88% had CA-125 tumour marker as negative.

Table no. 1: Incidence of ovarian tumours


Total no patients	973
Total no of patients with Ovarian tumours	50
Incidence of ovarian tumours	5.14

Table no. 2: Distribution of ovarian tumour patients according to age group

Age (Years)	Cases	Percentages (%)
≤30	10	20
31-40	12	24
41-50	13	26
≥ 51	15	30
Total	50	100

In present study, most of the patients (30%) with ovarian tumour were in the age

group 51 year old and above, followed by age group of 41- 50 years (26%). Least belonged to the age group of 31- 40 years (24%). (table 2)



Graph no. 1: Distribution of ovarian tumour patients according to age group

Table 3: Distribution of ovarian tumour patients according to histopathological type

Type of Tumour	Cases	Percentages (%)
Serous Cyst Adenoma	21	42
Mucinous Cyst Adenoma	9	18
Dermoid Cyst	3	6
Serous Cyst Adenocarcinoma	5	10
Mucinous Cyst Adenocarcinoma	7	14
Papillary Serous Cyst Adenocarcinoma	1	2
Papillary Mucinous Cyst Adenocarcinoma	3	6
Krukenberg Tumour	1	2
Total	50	100

In our study, among the study group of 50 patients, majority of (42%) were found to have serous cyst adenoma followed by mucinous cyst adenoma (18%). (table 3)

Table 4: Distribution of ovarian tumour patients according to management surgery

Operation	Cases	Percentages (%)
Cystectomy	23	46
TAHBSO	14	28
SL+ TAHBSO	11	22
EL+ Biopsy	2	4
Total	50	100

In present study, most common mode of management of ovarian tumour was cystectomy (46%) followed by total abdominal hysterectomy with bilateral salphingo oophorectomy seen in 28% cases. Exploratory laparotomy with biopsy was least carried out (4%). (table 4)

Table 5: Distribution of ovarian tumour patients according to complications

Complication	Cases	Percentages (%)
Torsion of Tumour	2	4
Recurrence	1	2
Death	3	6
No complication	44	88
Total	50	100

In present study, 88% of patients with ovarian tumour had no complication. 1 patient (1.66%) had recurrence, 1 patients (2%) had torsion of tumour.2 patients (4%) having ovarian tumour died due advanced ovarian neoplasm and disseminated carcinomatosis (table 5)

DISCUSSION

Ovarian cysts are a common genital disease in women and often cause symptoms, such as menstrual disorders and infertility, which have serious adverse effects on women’s physical and mental health.[7]In our study, out of 973 patents 50 were ovarian tumours. So the incidence was 5.14%. Similar findings were seen in Ganesh Tondage et al. (2020), where 5.92 was incidence of ovarian tumours.[8] M Yogambal et al. (2023) [9] where 5.36% was incidence of ovarian tumours. In a study by Dr. Vaddatti Tejaswini et al. incidence was higher about 7.02% [10] and in a study by Tarek Ramadan Abbasincidence was 2.31%. [11] Different incidence was observed in different studies because of different population, different study standards and different methodology used by the investigator.

In present study, 30% of ovarian tumour were found in age group >51 years. Whereas in the study by R Jha et al. ovarian tumour were seen maximum in age group <30 years (32.59%) [12]and study by Vaddatti Tejeswini et al., [10] and also in Ganesh Tondage et al. (2020), where 33.34 [8] ovarian tumour were seen maximum in age group of 31-40 years (29.49%). In present study, 62% of the patient had unilateral ovarian tumours, as similar to that of study of RK Mishra (96.31%) [13] and R Jha et al.[12] (87.57%). Both the studies were comparable to the present study. In present study, benign tumours were more commonly seen in 68% cases. In a study by Kanthikar et al. (2014) benign tumours were found in 78.57% [14]and malignant tumours were found in 20% patients. a study by Pilli et al. benign tumours wwere found in 75.2% patients. similar results were observed in previous studies. [15-17]

In present study, most common clinical presentation was pain in abdomen seen in 62% of cases. It is comparable to studies by Sumaira *et al.* (70.59%) [18], Tarek Ramadan Abbas *et al.*[11] (66.66%), Kanthikar *et al.*[14] (29.33%). Very few cases develop pressure symptoms like retention of urine, frequency of micturation, constipation in all studies. In present study, tumour marker CA-125 was positive in all of the malignant ovarian tumours. It was comparable to study by Habib KA. [19] In present study, on histopathological examination most common ovarian tumour was serous cyst adenoma seen in 40% of cases. It was comparable to the study by Kanthikar *et al.* [14] In present study, most common mode of management of ovarian tumour was cystectomy (42%) followed by total abdominal hysterectomy with bilateral salphingo oophorectomy seen in 28% cases. Exploratory laparotomy with biopsy was least carried out (4%). In our study, 88% of patients with ovarian tumour had no complication. 1 patient (2%) had recurrence, 2 patients (4%) had torsion of tumour. 3 patients (6%) having ovarian tumour died due advanced ovarian neoplasm and disseminated carcinomatosis . Conservative surgery is feasible only in young patients with borderline tumours, or endometrioid, mucinous, or serous Stage IA, grade I ovarian cancer.[20-22]

CONCLUSION

Most common mode of management of ovarian tumour was cystectomy (46%) followed by total abdominal hysterectomy with bilateral salphingo oophorectomy seen in 28% cases.

Source of Support: None Declared

Conflict of Interest: None Declared

REFERENCES

1. Ebell MH, Culp MB, Radke TJ. A systematic review of symptoms for the diagnosis of ovarian cancer. *Am J Prev Med* 2016;50:384-94.
2. Office for National Statistics. Cancer Survival in England: adult, stage at diagnosis and childhood – patients followed up to 2018 [Internet]. [Release date 2019 August 12; cited 2021 Mar 1].
3. Dutta DC. Text book of gynecology. 5th edition. Kolkatta : new central book agency (P) Ltd; 2009. Chapter 23, genital malignancy; p.321.
4. Baker TR, Piver SM. Etiology, biology and epidemiology of ovarian cancer seminars in surgical oncology. 1994;10:242-8.
5. Morgante G, Marka AL, ditto A, Leo VD. Comparison of two malignancy risk indices based on CA-125, ultrasound score and menopausal status in the diagnosis of ovarian masses. *Br J Obstet and gynecol.* 1999;106:524-527.
6. Marrow CP. Malignant and borderline epithelial tumor of ovary. *Gynaecologic oncology.* Malcolm copplesom ed. Churchil livingstone, London 1992, 2nd edition vol 2:889- 911.
7. Reinsch CS. Laparoscopic Ovarian Cystectomy. 2016.
8. Ganesh Tondage, Pushpadant Ruge. A study on anomalies in newborns and their association with fetomaternal factors. *MedPulse International Journal of Gynaecology.* May 2020; 14(2): 61-64.

9. Yogambal M. Arunalatha P. Chandramouleeswari K, Palaniappan V . IOSR Journal of Dental And Medical Science (IOSR-JDMS). 2014;13(2):74-80.
10. Veddatti T. Reddy ES. Premalatha P. Vahini G. Study of Morphological Patterns of Ovarian Neoplams. IOSR Journal of Dental And Medical Science (IOSR-JDMS). 2013;10(6):11-16.
11. Abbas TR. Matar ER. The Incidence and Histopathological Patterns of Ovarian Tumours in Bab Alshaaria University Hospital: Retrospective Study. Nat Sci 2015;13(4):37-41.
12. Jha R. Karki S. The histological pattern of ovarian tumours and their age distribution. Nepal Medical coll J. 2008;10(2):81-85.
13. Misra RK, Sharma SP, Gupta U, Gaur R, Mishra SD. Pattern of Overian Neoplasm In Eastern UP. J Obstet Gynaecol India. 1991;30:242-46.
14. Kanthikar SN. Dravid NV. Deore PN. Nilkumbh DB. Suryawanshi KH. Clinico-Histopathological Analysis of Neoplastic And Non-Neoplastic Lesions of The Ovary: A 3-Years Prospective Study In Dhule, North Maharashtra, India. J Clin Diagn Res. 2014 Aug; 8(8):4-7.
15. Pilli G, Sunita KP, Dhaded AV. Ovarian Tumours : A study Of 282 Cases. JIMA. 2002;100(7):1-6.
16. Saxena HMK, Devi G, Prakash P, Pankajam P. Ovarian Neoplasm: A Retrospective Study Of 356 Cases. J Obstet Gynaecol India. 1980;20(6):523-27.
17. Gupta N, Bisht D, Agarwal AK, Sharma VK. Retrospective and Prospective Study of Ovarian Tumours and Tumour Like Lesions. India J Pathol Microbial. 2007;50(3):525-27.
18. Sumaria Y . Aiman Y. Mohammad A. Clinicohistological Pattern of Ovarian Tumour in Peshwar Region. J Ayub Med Coll Abbottabad. 2008;20(4).
19. Habib KA, Jumaa MG, Hussein MJ. Determination of Serum a CA-125 and Evaluate its efficiency as screening tool for Early Detection of Ovarian Tumours. Baghdad Science Journal. 2015;12(11):51-61.
20. Benedet JL, Bender H, Jones H 3rd, Ngan HY, Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet. 2000 Aug;70:209-262.
21. Tropé C, Kaern J. Primary surgery for ovarian cancer. EJSO 2006;32:844-852.
22. Zanetta G, Rota S, Chiari S, Bonazzi C, Bratina G, Torri V *et al.*. The accuracy of staging: an important prognostic determinator in stage I ovarian carcinoma. A multivariate analysis. Ann Oncol. 1998;9:1097- 1101.